Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KLN-1010 |
| Synonyms | |
| Therapy Description |
KLN-1010 is an envelope-modified lentiviral vector designed to transduce T-cells in vivo and modify them to express a chimeric-antigen receptor (CAR) targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (Cancer Res (2024) 84 (6_Supplement): 48). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KLN-1010 | KLN1010|KLN 1010|KLN 001|KLN-001|KLN001 | TNFRSF17 Immune Cell Therapy 27 | KLN-1010 is an envelope-modified lentiviral vector designed to transduce T-cells in vivo and modify them to express a chimeric-antigen receptor (CAR) targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (Cancer Res (2024) 84 (6_Supplement): 48). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07075185 | Phase I | KLN-1010 | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma (inMMyCAR) | Recruiting | AUS | 0 |